

1 Article

2

Microencapsulation and Characterization of Natural 3 Polyphenols from PHF Extract

4 **Syed Ammar Hussain ^{1,†}, Ahsan Hameed ^{1,†}, Yusuf Nazir ¹, Tahira Naz ¹, Yang Wu¹, Hafiz Ansar
5 Rasul Suleria ^{2,3,4*}and Yuanda Song ^{1,*}**6 ¹ Colin Ratledge Center for Microbial Lipids, School of Agriculture Engineering and Food Science,
7 Shandong University of Technology, Zibo 255049, China; ammarshah88@yahoo.com (S.A.H),
8 ahsanhameed@outlook.com (A.H.); yusufnazir91@yahoo.com (Y.N.); nazkhan658@gmail.com (T.N.);
9 neverhangsome@hotmail.com (Y.W.)10 ² UQ Diamantina Institute, Translational Research Institute, Faculty of Medicine, The University of
11 Queensland, 37 Kent Street Woolloongabba, Brisbane, QLD 4102, Australia12 ³ Department of Food, Nutrition, Dietetics and Health, Kansas State University, Manhattan, KS 66506, USA13 ⁴ Centre for Chemistry and Biotechnology, School of Life and Environmental Sciences, Deakin University,
14 Piggdons Road, Wauru Ponds, Victoria 3216, Australia15 * Correspondence: hafiz.suleria@uqconnect.edu.au (H.A.R.S.); ysong@sdu.edu.cn (Y.S.); Tel.: +61-470-439-670
16 (H.A.R.S.); +86-139-06174047 (Y.S.)17 [†] These authors contributed equally to this work.18 **Abstract:** Microencapsulation of polyherbal formulation (PHF) extract was carried out by freeze
19 drying method, by employing gum arabic (GA), gelatin (GE), and maltodextrin (MD) with their
20 designated different combinations as encapsulating wall materials. Antioxidant components (*i.e*
21 total phenolic contents (TPC), Total flavonoids contents (TFC), and total condensed contents (TCT)),
22 antioxidant activity (*i.e.* DPPH, β -carotene & ABTS⁺ assays), moisture contents, water activity (aw),
23 solubility, hygroscopicity, glass transition temperature (T_g), particle size, morphology, *in vitro*
24 alpha-amylase and alpha-glucosidase inhibition and bioavailability ratios of the powders were
25 investigated. Amongst all encapsulated products, T_B (5% GA and 5% MD) and T_C (10% GA) has
26 proven to be the best treatments with respect to the highest preservation of antioxidant components
27 and their antioxidant potential by DPPH and β -carotene assays and noteworthy for an ABTS⁺ assays,
28 in addition, the aforesaid treatments also demonstrated lower moisture content, aw, particle size
29 and higher solubility, hygroscopicity and glass transition temperature (T_g). All freeze dried samples
30 showed irregular (asymmetrical) microcrystalline structures. Furthermore, T_B and T_C also illustrated
31 the highest *in vitro* anti-diabetic potential due to great potency for inhibiting alpha-amylase and
32 alpha-glucosidase activities. In the perspective of bioavailability, T_A , T_B and T_C demonstrated the
33 excellent bioavailability ratios (%). Furthermore, the phytochemo-profiling of ethanolic extract of
34 PHF was also revealed to find out the bioactive compounds.35 **KeyWords:** Microencapsulation; polyphenols; freeze-drying; antioxidant activity; *in vitro*
36 dialyzability; *in vitro* anti-diabetic potential.37

38

1. Introduction

39 Diabetes mellitus (DM) is the endocrine metabolic disorder characterized by increased blood
40 glucose level coupled with abnormality in protein, carbohydrate and fat metabolism. It has become
41 major disorder which affected 346 million people worldwide and this number is expected to be
42 double by the year of 2030 [1, 2]. It is such a progressive endocrine disorder of glucose metabolism
43 that eventually leads to micro- and macro-vascular changes causing secondary complications that are
44 incredibly challenging to manage [3]. Clinically, DM can be categorized into two types; Type-I DM,
45

46 arises due to the inadequate synthesis of insulin by β -cells of the pancreas and featured with
47 complications *i.e.* **diabetic retinopathy**, neurodegenerative, kidney-related issues **etc.** **it is an insulin-**
48 **dependent DM**, whereas, type-II DM; (*i.e.* non-insulin-dependent) is primarily characterized by
49 insulin resistance (*i.e.* a condition in which peripheral cells do not respond normally to insulin) or β -
50 cell dysfunction which eventually leads to diabetes-associated cardiovascular (CVD) and fatty liver
51 disease [4]. Diverse and multifaceted factors have played pivotal role for onset and progression of
52 DM, including unhealthy foods, auto-immune disorders, ecological factors and miscellaneous
53 variables [5-8]. However, “oxidative stress”, the ultimate outcome of reactive oxygen species (ROS)
54 and nitrogen oxide (NO), has been considered as one of the predominant factors as reported by
55 many studies [9-11].

56 To manage these ROSs, all living cells have intrinsic antioxidant manufacturing system, which
57 might helpful to retain the redox condition of the body at cellular and sub-cellular level by
58 neutralizing the reactive oxygen species (ROSs). The loss in balance between the free radical
59 production *i.e.* high ROSs production and biological system's ability to produce endogenous
60 antioxidants can lead to a aforementioned health-related disease called “oxidative stress” [12]. The
61 excess production of these ROSs are considered lethal for human health as their surplus generation
62 can leads to different patho-physiological conditions like fast aging process via damaging the nucleic
63 acids and changing in the conformation of proteins, heart-related disorders (*i.e.* CVDs), diverse types
64 of cancers, immunity related dysfunctions, inflammation, membranous lipid oxidation, decline of
65 hydroperoxide synthesis, neurodegenerative disorders, lungs and kidney illness, UV- irradiation,
66 and osteoporosis/ bone- related diseases. Direct correlation between oxidative stress and insulin
67 resistance (key factor for type-II DM) has been elaborated in mini review by Hurrel et al. [13].

68 Nowadays, research has been focused in exploring naturally occurring antioxidants to
69 circumvent the complexities due to oxidative stress. Diverse types of herbs, spices, teas, flowers,
70 seeds, fruits, vegetables and marine foods are now considered for the expected antioxidant excellent
71 sources to replace synthetic antioxidants [14-16]. Amongst naturally-occurring antioxidants,
72 polyphenols and their derivative compounds represented a diverse class of ubiquitous material *i.e.*
73 from simple molecules to complex configuration such as phenolic acids; hydroxybenzoic and
74 hydroxycinnamic acids, hydrolyzable and condensed tannins, and flavonoids, these are most
75 important compounds for nutraceutical, therapeutics and pharmacological point of view [14, 17] and
76 revealed various health endorsing activities: antioxidant activity via free radicals scavenging,
77 declining of hydroperoxide development, hampering the lipid oxidation, anti-diabetic, anti-malarial,
78 anticancer activity etc [14, 15].

79 Recently, polyherbal formulations (PHF)/ herbal nutraceuticals are considered as a great source
80 of natural polyphenols all over the globe due to their dynamic medicinal and therapeutic claims.

81 Previous investigations illustrated that selected individual plants contained abundant quantity
82 of polyphenols and their herbal combinations were found to produce best antioxidant activity among
83 all individual extracts due to synergistic effect. Synergism played a vital role via two different kind
84 of mechanism in context of interaction *i.e.*, pharmacokinetic (PK) and pharmacodynamics (PD) [18].
85 In the provisions of pharmacokinetic synergism, capacity of herbs/plant to aid in the absorption,
86 delivery, metabolism and elimination of the other herbs from the body was overlooked. Whilst in
87 pharmacodynamic synergism mechanism, assessment the synergistic effect when active components
88 with analogous therapeutic prospective are targeted to an interrelated physiological
89 structure/receptor. Here, combination of herbs may work on multiple targets at the same time to offer
90 a comprehensive relief [19]. Owing to synergism, polyherbal formulation (PHF) demonstrated vast
91 advantages over single herbal formulation (SHF) likewise: superior restorative effect can be attained
92 with a polyherbal formulation (PHF); to acquire enviable pharmacological accomplishment low
93 dosage would be required, consequently lessening the risk of harmful side effects. Additionally, PHF
94 facilitate the patient's convenience by eradicating the need of taking more than one formulation at a
95 time, which ultimately leads to better compliance and therapeutic effect. All the aforesaid advantages
96 have outcome in the attractiveness of PHF in the marketplace when compare to SHF [20].

97 Polyphenols are incredibly sensitive in diverse range of circumstances, during food processing
98 and storage practice likewise; high temperature of surrounding, incidence of oxygen and light, pH,
99 existence of oxidative enzymes, moisture contents [21]. The degradation of natural antioxidants may
100 hamper the possible effectiveness of application of these antioxidants in food /nutraceutical and
101 pharmaceutical applications and commercially available anti-diabetic drugs also produce
102 unconstructive effects on other metabolisms [22], so supplementation of anti-hyperglycemic
103 substances, which also possess antioxidant properties, might be an alternative therapy to overcome
104 this critical condition [23, 24]. To address these shortcomings and to augment the antioxidant stability
105 and preserve their diverse bioactivities including anti-inflammatory, anti-cancer, anti-microbial, anti-
106 diabetic capabilities, the microencapsulation has been employed successfully as a reliable technique
107 to circumvent the unwanted degradation of bioactive compounds, shielding them from adverse
108 environmental circumstances. Furthermore, various type of wall material has been used for
109 microencapsulation procedure, but cost effectiveness and physico-chemical distinctiveness must be
110 considered, including: hygroscopicity, biodegradability, emulsifying feature, adaptability to
111 gastrointestinal tract (GT), viscosity, solids content [25].

112 At present, the preferred wall materials for microencapsulation for various fruit juices and
113 plant/herbs extracts are maltodextrins (MD), gum arabic (GA) and gelatin (GE) [26]. Maltodextrin of
114 various dextrose equivalents (DE) are generally used as wall material owing to their distinct
115 characteristics likewise; low viscosity, high solubility in water and their solutions are monochromic
116 in appearances. These features made them frequently used carrier/wall materials in the micro-
117 encapsulation procedure. Gum Arabic (GA) (exudates of acacia), owing to its unique features *i.e.*
118 naturally colorless, low viscosity, high retention of volatiles and ability to make stable emulsion is
119 ultimately considered as excellent encapsulating agent whereas its high economic cost provoked
120 researcher for full or partial replacement of the encapsulation agent [26-28]. In addition, gelatin
121 (GE), is also a better option for microencapsulation because of its superior characteristics for
122 emulsification, film-formation, water solubility, last but not least ability to form finer dense complex.
123 According to Fang and Bhandari [29], a sole microencapsulating agent has limitation over all required
124 attributes to improve microencapsulation effectiveness, eventually has been resolved by using
125 different combination of polymers due to their diverse features. The selection for polymer's
126 combinations which possibly consequence in superior microencapsulating efficiency and regarded
127 economically suitable than the single biopolymers has been becoming the point of emerging interest
128 [29, 30].

129 In the current study, polyherbal formulation (PHF) was firstly made with equal ratio of roots of
130 *Chlorophytum borivilianum*, roots of *Astragalus membranaceus*, roots of *Eurycoma longifolia*, and seeds of
131 *Hygrophila spinosa* T. Anders having previously proven diverse ethno-pharmacological applications
132 [31-34] as polyphenols enriched nutrient supplement, then PHF extract was further
133 microencapsulated by freeze drying method using different wall materials, subsequently antioxidant
134 components (*i.e.* TPC, TFC, and TCT), antioxidant activity (*i.e.* DPPH, β -carotene & ABTS⁺ assays),
135 anti-diabetic potential (*i.e.* *in vitro* alpha-amylase and alpha-glucosidase inhibition) physical property
136 like; moisture contents, water activity (aw), solubility, hygroscopicity, glass transition temperature
137 (T_g), morphological characteristics (*i.e.* particle size, morphology), and bioavailability ratios of the
138 microencapsulated powders were investigated. In last, the chemo-profiling for ethanolic extract of
139 PHF was also studied.

140 2. Materials and Methods

141 2.1. Materials, chemicals, reagents and encapsulating agents

142 All different parts of herbs (detail in Section 3.2) were purchased from Faisalabad-Pakistan and
143 their identification and respective characteristics were authenticated by Prof. M. Jafar Jaskani from
144 Institute of Horticulture, University of Agriculture Faisalabad (UAF) Pakistan. All chemicals used
145 were of analytical grade or higher where suitable. DPPH (2, 2-diphenyl-1-picryl-hydrazyl), Foline-
146 Ciocalteu (FC), β -carotene, Butylated hydroxytoluene (BHT), TWEEN 20, quercetin, Sodium

173 carbonate, ABTS (2, 20-azinobis (3-ethylbenzothiazoline-6-sulphonic acid), α -tocopherol, Linoleic
174 acid, (+)-catachin, quercetin, AlCl₃.6H₂O, HCl, Vanilline, NaOH, Potassium persulfate, Trolox,
175 gallic acid were purchased from Sigma-Aldrich GmbH (Sternheim, Germany). Alpha-amylase
176 from porcine pancreas, alpha-glucosidase from *Saccharomyces cerevisiae*, paranitrophenyl-
177 glucopyranoside, pepsin (porcine-7000), bile salts pancreatin (p-1750), piperazine-NN-bis (2-ethane-
178 sulfonic acid) di-sodium salt (PIPES), gelatin (GE), HPLC-grade methanol, acetonitrile ethanol,
179 acetone were supplied by Sigma-Aldrich (USA), soluble starch (extra pure) was obtained from J. T.
180 Baker Inc, Phillipsburg, USA. Ultra-pure water (18 M Ω cm⁻¹) was acquired from Milli-Q
181 purification device (Millipore Co. USA). Sodium hydrogen carbonate was purchased from Merck
182 (Germany). Sea sand was of 200-300 grain size from Scharlau (Barcelona, Spain). The encapsulating
183 agents were: gum arabic (GA) (Sangon Biotech, Co. China), maltodextrin (MD) (Dextrose equivalent
184 of 12) was purchased from Corn Products (Cabo de Santo Agostinho, Pernambuco, Brazil)

185 *2.2. Polyherbal formulation (PHF)*

186 Polyherbal formulation (PHF) was made by combining the root of *Chlorophytum borivilianum*
187 roots of *Astragalus membranaceus*, roots of *Eurycoma longifolia*, and seeds of *Hygrophila spinosa* T.
188 Anders, in a ratio of 1:1:1:1 respectively.

189 *2.3. Preparation of sample*

190 Firstly, the roots and seeds of aforesaid herbs were cut into small pieces, followed by thorough
191 washing with deionized water in order to avoid any contamination. The PHF material was then dried
192 for 12 days in dark in well ventilated room at room temperature (23 \pm 8), and subsequently grounded
193 with mortar and pestle to make crude powder with the help of liquid nitrogen, until a uniform sieve
194 size equivalent to (1.0 mm) was achieved. The resulting powder was stored at -80°C in inert vacuum
195 bags until used for extraction as followed.

196 *2.4. Pressurized liquid extraction (PLEx)*

197 PLEx was executed in a Dionex ASE 350 system (Dionex, Sunnyvale, CA) with the powder of
198 PHF obtained as mentioned above. Aliquot of 5.0g of powder of PHF was mixed with diatomaceous
199 earth (1/1) and placed in a 34mL stainless-steel cells. The extraction was performed *via* 3
200 consecutively applied steps with absolute solvents of increasing polarity, in order to get the
201 maximum possible number and amount of secondary metabolites of various polarities and
202 miscibilities, namely, acetone, ethanol, methanol and their aqueous mixtures with water (1:10, 3:10),
203 and pure water. Extraction time was of 22 minutes; pressure 10.6 MPa; temperature 75 °C (for
204 acetone, ethanol and methanol) and 135 °C (for water). Organic solvents were removed in a rotary
205 vacuum evaporator at 38 °C, while the residual water was removed in a freeze drying unit. The
206 extracts after solvent evaporation were placed under nitrogen flow for 20 min and stored in dark
207 glass bottles at -80 °C until analyzed.

208 *2.5. Development of microencapsulated powder products*

209 In order to prepare the particular dispersions, 100mL of PHF aqueous extract was mixed
210 individually with different preselected combination of microencapsulating wall materials as follow:
211 A (5% GA and 5% GE) (hereafter referred and discussed as T_A); B (5% GA and 5% GE) (hereafter
212 referred and discussed as T_B), C (10% of GA) (hereafter referred and discussed as T_C), and D (10% of
213 MD) (hereafter referred and discussed as T_D), under constant shaking with 220 rpm, at 35°C for 30
214 min by a shaking unit (Shanghai, CIMO). Afterward, these dispersions/emulsions were
215 microencapsulated through lyophilization process for formulating four distinctive treatments. *i.e.* T_A,
216 T_B, T_C, T_D.

217 For microencapsulation by means of freeze-drying process, the above-mentioned
218 dispersions/emulsions were kept at -20°C (freezer) for 48 h. Subsequently, the samples were placed
219 in lyophilization unit (Labconco, Germany) for freeze drying at -56.5°C, with vacuum pressure of

220 20µmHg for 60 h. After the completion of freeze drying process, the samples were crushed utilizing
221 a mortar and pestle assembly. Finally, the desirable final microencapsulated products were sealed in
222 polyethylene bags and aluminum pouches as well and stored in desiccator encompassing silica until
223 further analysis.

224 *2.6. Determination of bioactive compounds and their bioactivities after microencapsulation*

225 Bioactive components which were determined after the microencapsulation were total phenolic
226 compounds (TPC), total flavonoids compounds (TFC), total condensed tannins (TCT). While the
227 bioactivities of the microencapsulated powders were measured in terms of total antioxidant activity
228 determined by β -carotene bleaching assay (TOAA), ABTS⁺ radical scavenging activity, and DPPH
229 scavenging capacity. All these spectrophotometric analysis were performed according to previously
230 developed methods with minor alteration [16, 35, 36]. The results for ABTS⁺ radical scavenging
231 activity are deliberated as EC₅₀ values (mg of extract/mL) for comparison. Effectiveness of antioxidant
232 properties is inversely correlated with EC₅₀ value.

233 *2.7. Determination of the physical properties of the microencapsulated powders*

234 *2.7.1 Moisture content*

235 The moisture contents of the microencapsulated products were estimated by using the method
236 describes in manual AOAC [37], *i.e.* by calculating the loss of sample after weight after heat up at
237 105°C.

238 *2.7.2 Water activity (Aw)*

239 The water activity (Aw) of all lyophilized samples was calculated through the direct analysis in
240 electronic meter (Aqualab Dew Point 4TEV, USA), to gain the constant state the samples were firstly
241 placed at 25°C for at least 15 mints.

242 *2.7.3 Solubility*

243 The solubility of microencapsulated products was measured by the method described by Cano-
244 Chauca et al. [38], with minute alterations. The sample's quantity of 1.0g was mixed up with 100mL
245 distilledwater in beaker and stirred with magnetic stirrer(MS-H-S10) for 20mints. After that the
246 centrifugation of solution carried out at 3000 \times g (Thermo Scientific) for10mints. The quantity of 25mL
247 of the supernatant was transferredto a petriplates (pre-weighted) and dried in oven at 105°C for 4.0
248 h.The solubility was measured as a result of weight difference and demonstrated in the term of
249 percentage (%).

250 *2.7.4 Hygroscopicity*

251 For the estimation of the hygroscopicity, the encapsulated powder of 1.0 g was placed in
252 dessicator with saturated NaCl solution (74.6%) at temperature of 25°C. After 1 week, samples were
253 weighed and hygroscopicity was represented in the term of percentage (%) [39].

254 *2.7.5 Glass transition temperature (Tg)*

255 The glass transition temperature (Tg) of the microencapsulated products was calculated by
256 means of differential scanning calorimetry (DSC) (DSC-2000-New Castle, DE). The weight of 7-8mg
257 of sample was placed in aluminum hermetic pots. For the reference purpose, a aluminum pan
258 without sample was used. Ultra-pure nitrogen N₂ was used as purge gas (flow rate 50 mL/min). The
259 temperature ranged from -80 °C to 120 °C at a heating rate of 40 °C/ min. The glass transition
260 temperature was determined by utilizing software of TA Universal Analysis 2000.

261

262 2.8. Morphology and size distribution

263 The configuration of micro-particles obtained from diverse encapsulating wall material and their
264 combinations were examined by scanning electron microscope (Quanta 250 E FI). At first, very minute
265 was fixed on surface of double sided tape of carbon then finally evaluated the samples under
266 microscope with 400 X magnification. The analysis for particle size distribution average and particle
267 size was conducted by the means of ImageJ (NIH, Bethesda, MD).

268 2.9. *In vitro* Assays

269 2.9.1. Alpha-Amylase Inhibition Assay

270 The inhibition of alpha-amylase was determined using an assay modified from the Worthington
271 Enzyme Manual [40]. Aliquot 0 - 4 mg/ml in DMSO (v/v 1:1) of each encapsulated PHF samples was
272 prepared and 500 μ l of each sample were mixed with 500 μ l of 0.02 M sodium phosphate buffer (pH
273 6.9) containing α -amylase solution (0.5 mg/ml) and incubated at 25°C for 10min. After pre-incubation,
274 500 μ l of a 1% starch solution in 0.02 M sodium phosphate buffer (pH 6.9) was added to each tube at
275 timed intervals. The reaction mixtures were then incubated at 25°C for 10 min. The reaction was
276 stopped with 1.0 ml of dinitrosalicylic acid colour reagent. The test tubes were then incubated in a
277 boiling water bath for 5 min and cooled to room temperature. The reaction mixture was then diluted
278 by adding 15 ml of distilled water, and the absorbance was measured at 540 nm using a micro-plate
279 reader (Thermomax, Molecular device Co., Virginia, USA). The experiments were performed in
280 duplicate and the absorbance of sample blanks (buffer instead of enzyme solution) and a control
281 (buffer in place of sample extract) were also recorded. The absorbance of the final each encapsulated
282 PHF sample was obtained by subtracting its corresponding sample blank reading. Acarbose was
283 prepared in distilled water and used as positive controls

284 The percentage inhibition was calculated using the formula;

$$285 \text{ % Inhibition} = \{(Ac - Ae)/Ac\} 100$$

286 Where Ac and Ae are the absorbance of the control and extract, respectively

287 IC₅₀ values (inhibitor concentration at which 50% inhibition of the enzyme activity occurs) of
288 each encapsulated PHF samples was prepared were determined by plotting graph with varying
289 concentrations of the plant extracts against the percent inhibition.

290 2.9.2. Alpha-Glucosidase Inhibition Assay

291 The alpha-glucosidase was assayed using a method modified by Apostolidis et al. [41]. Aliquot
292 of 0 - 4 mg/ml in DMSO (v/v 1:1) of each encapsulated PHF samples were prepared. 50 μ l of each
293 concentration sample was mixed well with 100 μ l of 0.1 M phosphate buffer (pH 6.9) containing α -
294 glucosidase solution (1.0 U/ml) and the mixtures were then incubated in 96-well plates at 25°C for 10
295 min. After pre-incubation, 50 μ l of 5 mM p-nitrophenyl- α -D-glucopyranoside solution in 0.1 M
296 phosphate buffer (pH 6.9) was added to each well at timed intervals. The reaction mixtures were
297 incubated at 25°C for 5 min. Before and after incubation absorbance readings were recorded at 405
298 nm using a micro-plate reader (Thermomax, Molecular device Co., Virginia, USA) and compared to
299 a control which contained 50 μ l of the buffer solution instead of the extracts. The experiments were
300 performed in triplicate and the α -glucosidase inhibitory activity was expressed as percentage
301 inhibition. Acarbose was prepared in distilled water and used as positive controls. The percentage
302 inhibition was calculated using the formula;

$$303 \text{ % Inhibition} = \{(Ac - Ae)/Ac\} 100$$

304 Where Ac and Ae are the absorbance of the control and extract respectively.

305 IC₅₀ values (inhibitor concentration at which 50% inhibition of the enzyme activity occurs) of
306 each encapsulated PHF samples was determined by plotting graph with varying concentrations of
307 the plant extracts against the percent inhibition

308

309 2.9.3. Determination of Bioavailability of microencapsulated products by in vitro dialyzability
310 assay

311 The estimation for bioavailability of all microencapsulated products was determined by the
312 method developed by Pineiro et al. [42].

313 *2.10. Acute toxicity*

314 The acute oral toxicity study was carried out in compliance with Organization for Economic
315 Cooperation and Development (OECD) guideline 425 [43]. All mice ($n=5$) for testing were fasted for
316 12 h and weigh have been recorded and subsequently received the solution of microencapsulated
317 products of PHF at the final concentration of 2000 mg/kg by gavage. The animals were observed
318 individually at least once during the first 30 min after dosing, periodically for first 24 h and regularly
319 thereafter for 14-day of feeding period for gross behavioral changes, toxicity symptoms or mortality.

320 *2.11. LC-ESI-QTOF-MS analyses*

321 For LC-ESI-QTOF-MS analysis, firstly ethanolic extract was prepared using PLEX as described
322 in Section 3.4. Afterwards obtained ethanolic extract was used to for the metabolite profiling of PHF
323 using an Agilent 1100 Liquid Chromatography system (Agilent Technologies, Palo Alto, CA, USA)
324 furnished with a standard auto-sampler. The analytical column used was characterized as
325 Phenomenex Gemini C18 (3 μ m, 2 x 150 mm) operated at 25°C with a gradient elution portfolio at a
326 flow rate of 0.2 ml/min. The mobile phases used were of acidified water (0.5% acetic acid) (A) and
327 acetonitrile (B). The following multi-step linear gradient applied in following fashion: 0 min, 5% B; 5
328 min, 15% B; 25 min, 30% B; 35 min, 95% B; 40 min, 5% B. The initial conditions were maintained for 5
329 min. The injection volume of sample in system was 1 μ l. The LC-MS system was further composed of
330 a Dionex Ultimate 3000 Rapid Separation LC system coupled to a micrOTOF QII mass spectrometer
331 (Bruker Daltonics, Bremen, Germany) fitted with an electro-spray source operating in positive mode.
332 The LC system contained an SRD-3400 solvent rack/degasser, an HPR-3400RS binary pump, a WPS-
333 3000RS thermostated auto-sampler, and a TCC-3000RS thermostated column compartment. The
334 micrOTOF QII source parameters were as follows: temperature, 200°C; drying N₂ flow, 8 L/min;
335 nebulizer N₂, 4.0 bar; end plate offset, -500 V; capillary voltage, -4000 V; mass range, 50–1500 Da,
336 acquired at 2 scans/s. Post acquisition internal mass calibration used sodium formate clusters with
337 the sodium formate delivered by a syringe pump at the start of each chromatographic analysis.
338 Nitrogen was used as drying, nebulizing and collision gas. The precise mass data of the molecular
339 ions were processed using Data Analysis 4.0software (Bruker Daltoniks), which delivered a list of
340 potential elemental formulas via the Generate Molecular Formula Editor. The generate molecular
341 formula Editor uses a CHNO algorithm, which deals with standard practicalities such as electron
342 configuration, minimum/maximum elemental range and ring-plus double-bond equivalents, as well
343 as a sophisticated comparison of the theoretical with the measured isotope pattern(Sigma Value) for
344 increased confidence in the recommended molecular formula. The commonly acknowledged
345 accuracy threshold for validation of elemental compositions was established at 5 ppm (Bringmann et
346 al., 2005). It is significant to point out that even with very high mass precision (<1ppm) many
347 chemically likely formulas may be found, subjected to the mass regions considered and so high mass
348 accuracy alone is not enough to discount enough candidates with complex elemental compositions.
349 The use of isotopic abundance patterns as a single further constraint, however, eliminates>95% of the
350 false candidates. This orthogonal filter can diminish numerous thousand nominees down to only a
351 small number of molecular formulas. During the development of the HPLC method, the instrument
352 was calibrated externally with a 74900-00-05 Cole Palmer syringe pump (Vernon Hills, Illinois, USA)
353 directly linked to the interface and injected with a sodium acetate cluster solution containing 5mM
354 sodium hydroxide and 0.2% acetic acid in water: isopropanol (1:1, v/v). The calibration solution was
355 injected at the beginning of each run and all the spectra were calibrated prior to compound
356 identification. By using this method, an exact calibration curve based on several cluster masses, each
357 differing by 82 Da (NaC₂H₃O₂) was obtained. Due to the compensation of temperature drift in the

358 micrOTOF-Q II, this external calibration provided accurate mass values of better than 5 ppm for a
359 complete run without the need for a dual sprayer setup for internal mass calibration.

360 3. Statistical Analysis

361 All statistical analyses were conducted using a one-way analysis of variance using Dunnett's
362 comparison tests or unpaired t-tests. All calculations were carried out using GraphPad Prism 5
363 (GraphPad Software, San Diego CA, www.graphpad.com). Significance was observed at $p < .05$.

364 4. Results and discussion

365 4.1. The effect of microencapsulation on the contents of antioxidant components and antioxidant activity of 366 PHF

367 The contents of antioxidant components of PHF extract treated with different encapsulating wall
368 materials were shown in Table 1. In comparison to untreated extract, all microencapsulated
369 treatments have less antioxidant components (*i.e.* total phenolic contents (TPC), total flavonoids
370 contents (TFC), and total condensed tannins (TCT). The retention for all freeze-dried treatments
371 demonstrated in the term of percentages, ranged from 94.28% to 68.22% for TPC, 76.46% to 40.35%
372 for TFC and 79.24% to 59.70% for TCT representing the effectiveness of microencapsulation
373 procedure. The wide-ranging powders produced from the microencapsulation process, especially
374 those obtained from the treatment C (T_c), retained higher contents of antioxidant components. In
375 general, these results may be associated with the type and concentrations of different wall materials.
376 There were many multifaceted factors which were responsible for hammering of polyphenol
377 compounds during freeze drying method, the crushing of lyophilized microencapsulated products
378 after freeze-drying, was considered one of the key factor which may cause the degradation of
379 bioactive components in the final products by boosting the product's contact with environment. Our
380 finding was in agreement with previous work in which authors explored that lyophilized wine
381 product contained almost 70% of the original phenolics components [44-45]. Other factors which may
382 responsible for declining the concentration of active components include: formation of microspheres
383 during the lyophilization due to a scattering of the bioactive components inside the configuration of
384 encapsulating wall materials *i.e.* consisting of one or more constant phase of encapsulating agents
385 [46], development of micro-pores in the aforesaid microspheres, mainly associated to sublimation
386 process during lyophilization [47]. In the current study, lyophilized product encompassed a
387 reduction of 5.72–31.78% for total phenolics contents (TPC), declined trend of 23.54–59.65% and 20.76–
388 40.30% was also observed for TFC and TCT respectively. Despite the reduction of antioxidant
389 components of microencapsulated products, a significant retentions were also observed (described
390 above in detail with percentages) comparable/higher to prior studies *i.e.* authors found, that acai pulp
391 microencapsulated with GA have phenolic retention of 94.1% [26].

392 The freeze dried product microencapsulated with 10% GA demonstrated (T_c) the exceptional
393 conservation for antioxidant components (*i.e.* TPC, TFC, TCT). The order of effectiveness of
394 microencapsulation for other remaining treatments was as followed: $T_B > T_A > T_D$. The higher
395 competence of T_c treatment was mainly attributed to the structure of gum arabic (GA), because it is
396 a hetero-polymer made up of dense branches of sugar, containing a minute quantity of protein which
397 connected to the carbohydrate skelton via covalent bonds, proceeding as a tremendous
398 microencapsulating material [48]. Noteworthy results were also found for T_B and T_A , which might be
399 credited to presence of 5% GA. In contrary, no significant difference was noticed for the lyophilized
400 product having 10% MD as wall material (T_D).

401 The antioxidant activity for microencapsulated powders determined by DPPH, β -carotene and
402 ABTS⁺ assay were illustrated in Table 1. All microencapsulated products had showed decrease
403 antioxidant by DPPH assay in relation to original extract (control) and their retention ranged from
404 38.84% - 64.50%. Treatment B (5% GA and 5% MD) and treatment C (10% GA) illustrated the highest
405 antioxidant activity; these results were agreement with previously found values by Souza et al. [49].
406 The order for effectiveness was noticed as: $T_B > T_c > T_A > T_D$. In the case of β -carotene bleaching assay,

407 the antioxidant retention for all microencapsulated products were explored from 77.59 to 93.93% in
408 comparison to original extract, T_B (5% GA &5% MD) showed maximum value for antioxidant
409 activity in a similar way as in DPPH assay. Remaining treatments has been categorized in context of
410 efficacy as followed: $T_C > T_D > T_A$. Referring to antioxidant assay by ABTS⁺ radical scavenging activity,
411 the range of retention was from 62.2% to 86.68%. The noteworthy consequence was revealed for T_A
412 (5% GA & 5% GE), while T_B (5% GA and 5% MD) and T_C (10% GA) also illustrated the significant
413 results with retention of 75.27% and 74.18% respectively. The above discussion suggested the
414 worthiness of diverse antioxidant assay for secure and overwhelming conclusion, because each assay
415 comprised its own precision and proceeds at a challenging site of action. Amongst the all
416 lyophilized encapsulated products, the antioxidant activity was higher in T_B and T_C , being related to
417 the presence of high antioxidant components (*i.e.* TPC, TFC &TCT) (Table 1), which provided an
418 excellent defense system against unrestrained oxidation, owing to its high reducing power.
419 Furthermore, there is no report yet on microencapsulation of aforesaid polyphenol enriched extract
420 from PHF and their characterization related to analysis for antioxidant.

421 4.2. Physical characteristics of microencapsulated powder products

422 Physical factors *i.e.* water activity; moisture contents and hygroscopicity are indispensable for
423 encapsulating products steadiness and storage, whilst aqueous solubility is correlated with ability of
424 powder products for reconstitution [28].

425 The moisture contents for four different lyophilized encapsulated products were demonstrated
426 in Figure1A. The moisture content of said powders was ranged from 7.07% to 9.04%; on the contrary,
427 no significant difference was found between T_B and T_D (7.41% and 7.21%, respectively). Our findings
428 was validated by earlier investigation which elaborated the moisture contents for blackberry fruit
429 drink encapsulated by means of MD and trehalose dehydrate were of 2.44–6.11% [50]. Lower freezing
430 temperature *i.e.* less than -40°C consequence in quick freezing, eventually caused tiny pores in the
431 superficial coatings, which might encumber the mass transfer and regarded as an obstacle for
432 sublimation process, causing the higher retention of moisture contents in microencapsulated
433 products [51].


434 The water activity (a_w) of all microencapsulated products (Figure 1B) was ranged from 0.310 to
435 0.450, and all final encapsulated products were noticeably dissimilar from one another, apart from T_B
436 (5% GA and 5%MD). T_D (10% MD) demonstrated the maximum a_w value of 0.450 which was
437 corroborating with previous study carried out by Gurak et al. [52] who found that a_w of grape fruit
438 drink microencapsulated by the means of maltodextrin (MD) utilizing lyophilization technique was
439 0.430.


440 Various factors that determine the solubility of the microencapsulated powdered products
441 includes: the feed composition and particle size. The selection of the wall material is very important,
442 not only for the solubility itself but also to the crystalline state that ultimately bestowed to the dried
443 powders [53]. The aqueous solubility for all lyophilized treatments was ranged from 84.06 to 92.31%
444 as illustrated in Figure1C. The solubility of the final product possibly not only associated with
445 solubility prospective of microencapsulating wall material but also on attainted particle size in final
446 desirable product; if particle size would be minute, it would ultimately provide the better surface
447 area's availability for the hydration process [54, 55]. The highest solubility value was obtained for
448 treatment T_D (10% MD) that was consistent with previous work. Moreira et al. [30] elaborated the
449 solubility percentage for acerola pomace extract ranged from 90.97 to 96.92%, using MD and tree's
450 gum of cashew apple as microencapsulating wall materials.

451 The hygroscopicity values for all microencapsulated powder products by the means of freeze-
452 drying method were depicted in Figure 1D. These were ranging from 11.92% to 14.35%, representing
453 a lesser amount of hygroscopicity values for powder products; hence assisted the protection of
454 antioxidant components. The findings of current work have much resemblance with preceding work,
455 utilizing related sort of microencapsulating wall materials. Some renowned investigators reported
456 the hygroscopicity of microencapsulated products made up from bark extract of jaboticaba tree using
457 MD and GA as wall material of 17.75%. The lyophilized powdered products demonstrated the lesser

458 hygroscopic values, regardless the presence of higher contents of moisture [25]. The aforesaid
 459 behavior was also reported by Khazaei, et al. [31]. The lower values of hygroscopicity for the all
 460 lyophilized products mainly attributed to the bigger particle size, since the bigger the particle size,
 461 the lesser the uncovered surface area, therefore low down the water absorption [26, 58].

462 The stability of microencapsulated powdered products for the period of storage was principally
 463 determined by glass transition temperatures (T_g), the lower the T_g resulting in lower the stability of
 464 final product and vice versa. The glass transition temperatures (T_g) of all lyophilized products were
 465 of 15.86 to 45.0°C in range (Figure 1E). Amongst all lyophilized microencapsulated products, the T_c
 466 represented the highest glass transition temperature (45.0°C), proving maximum stability.
 467 Furthermore, other treatments also showed significant values for T_g except T_d . The glass transition
 468 temperature has been influenced by diverse factors, including moisture contents, chemical
 469 configuration and molecular mass of subjected matter [59]. Adhikari et al., 2004 found the lower
 470 transition temperatures of fruit drinks/extract were mainly due to the existence of elevated quantity
 471 of low molecular weight organic acids and polysaccharides [60]. Additionally, integration of
 472 microencapsulating agents in extracts has much predisposed on glass transition temperatures (T_g)
 473 which varied according to molecular weight of encapsulating material; increase in molecular weight
 474 of wall material resulting the increase in final T_g of the product. The results of our current work were
 475 corroborated with earlier findings [61-63]. The lyophilized microencapsulated product obtained from
 476 treatment D (T_d) represented the lower T_g because of lower molecular weight of MD. Moreover, this
 477 behavior was not noticed in T_c (10%GA), T_a (10% GA and 5% GE) and T_b (10%GA and 5%MD) due
 478 to the existence of uppermost molecular weight of GA in the term of quality and quality of wall
 479 material.





481

482

483

484 **Figure 1(A-E):** Physical properties of PHF extract microencapsulated with GA, GE, MD and their
 485 combinations by freeze-drying method. 1F: bioavailability ratio (%), & 1G and 1H: alpha-amylase and
 486 alpha-glucosidase inhibition activity (IC50). Treatment A (TA): Freeze-dried, with 5% GA and 5% GE;
 487 Treatment B (TB): Freeze-dried, with 5% GA and 5% MD; Treatment C (TC): Freeze-dried, with 10%
 488 GA; Treatment D (TD): Freeze-dried, with 10%.

489

490

491

Table 1: Antioxidant components and antioxidant activities of PHF extracts microencapsulated with GA, GE, MD and their combinations by Freeze-drying method

Treatments	TPC *	TFC **	TCT ***	DPPH ****	^a Beta-carotene	^b ABTS
Control	26.72 ± 0.61 ^a	6.848 ± 0.05 ^a	15.72 ± 0.3 ^a	133.3 ± 1.79 ^a	83.39 ± 0.79 ^a	3.687 ± 0.03 ^a
TA	22.89 ± 0.41 ^b	2.76 ± 0.03 ^d	9.383 ± 0.16 ^d	74.73 ± 4.6 ^{d,e}	64.71 ± 0.64 ^{d,e}	3.197 ± 0.95 ^b
TB	24.26 ± 0.085 ^a	4.183 ± 0.07 ^b	10.1 ± 0.13 ^c	85.2 ± 0.5 ^b	78.34 ± 0.51 ^b	2.777 ± .125 ^c
TC	25.26 ± 0.22 ^a	5.233 ± 0.15 ^a	12.46 ± 0.021 ^b	78.11 ± 1.67 ^c	75.4 ± 0.88 ^c	2.733 ± 0.06 ^c
TD	18.27 ± 0.15 ^c	3.817 ± 0.03 ^c	9.383 ± 0.07 ^d	51.52 ± 0.72 ^f	65.72 ± 0.92 ^{d,e}	2.285 ± 0.072 ^{d,e}

Note: Results displayed are a representation of triplicate quantifications per extract. Different letters within the same column indicate significant differences ($p < 0.05$) * Total phenolic contents (TPC) expressed as mg gallic acid equivalents (GAE) per g of dry extract; **Flavonoid content expressed as mg quercetin equivalents (QE) per g of dry extract; ***Total condensed tannin content based on calibration curve of (+)-catechin, expressed as mg catechin equivalents (CE) per g of dry extract. ****DPPH expressed as $\mu\text{mol/g}$ sample on dry basis; ^a β -carotene of extracts (5 mg/mL) based on percent bleaching inhibition. ^b EC₅₀ (mg/mL) is representative of the effective concentration at which 50% of ABTS⁺ radicals were scavenged. The Dunnett's test was to evaluate the significance with confidence level was set to 95%. TA: Freeze-dried, with 5% GA and 5% GE; TB: Freeze-dried, with 5% GA and 5% MD; TC: Freeze-dried, with 10% GA; TD: Freeze-dried, with 10%.

492

493

494


495

496


497

498 4.3. Size distribution and Morphology of Microencapsulated powders


499 Different polymers exhibited particular protection capacity, so the evaluation of
 500 microencapsulated products is very crucial. This aforesaid capacity elaborated the extent of micro-
 501 pores and reliability of encapsulated micro-particles [64]. The structural analysis of the encapsulated
 502 products from the lyophilization methodology was conducted by the means of scanning electron
 503 microscope (Quanta 250 EFI). Comparison of the images illustrated the noticeable variation in term
 504 of particle structure and size allocation amongst the different microencapsulated products and their
 505 combination attained after lyophilization. Figure 2A, 2B, 2C, 2D demonstrated the morphology of all
 506 freeze-dried microencapsulated products. As can be seen all lyophilized products presented the
 507 irregular shape like broken glass with appreciable proportion of pores on surface. The outcome of
 508 current investigation has agreement with the recent work explored by Kuch and Norena [65]. These
 509 authors studied on morphological aspects of lyophilized products, made up from the peel of grapes
 510 and pomace of *Averrhoa carambola* and presented the final product as porous, uneven and brittle
 511 confirmation; furthermore they also described the reason behind the high porosity of lyophilized
 512 products as development of ice crystals had happen in material which as a result retarded the
 513 breakdown of final configuration and hence less change in volume occurred.




Treatment A (TA)



Treatment B (TB)



Treatment C (TC)



Treatment D (TD)

514 Figure 2: Micrographs of PHF extract microencapsulated with GA, GE, MD and their combinations
 515 by freeze-drying method. Treatment A (TA): Freeze-dried, with 5% GA and 5% GE; Treatment B:
 516 Freeze-dried, with 5% GA and 5% MD; Treatment C (TC): Freeze-dried, with 10% GA; Treatment D
 517 (TD): Freeze-dried, with 10%.

518 There was a direct association between span value and dispersal of particle size, the lesser span
519 value demonstrating a uniform distribution of micro-particles [66]. The size of micro-particles from
520 the final products was in the range of 18.08 to 391.30 μm . T_A explored the higher particle size (more
521 than 287 μm), whereas T_D showed the lowest one. Our current work is consistent with prior
522 investigation, examined by other authors [58] who found that the particle size of microencapsulated
523 product via freeze-drying method reached up to 300 μm . The bigger particle dimension of lyophilized
524 products was mainly attributed to rapid freezing and less availability of force to crush the freeze drop
525 during lyophilization [67, 68]. Moreover, particle size was also influenced by crushing procedure
526 which was generally accustomed for size reduction after lyophilization.

527 *4.4. Alpha-Amylase & Alpha-Glucosidase Inhibition*

528 Type-II DM an outcome of insulin resistance is a metabolic disease that, according to the latest
529 data for the World Health Organization in 2014, impinges on 9% of the world's population, both in
530 developed and developing countries, and directly caused 1.5 million deaths in that single year [1, 2].
531 In order to hamper the side effects of type-II DM, insulin injection and usage of anti-
532 hyperglycaemic substances are two key conventional approaches. The management of the blood
533 sugar level is effective and novel approach to overcome the diabetes mellitus and related
534 complications. Inhibitors of carbohydrate hydrolyzing enzymes (i.e.: α -amylase and α -glycosidase)
535 have been practically valuable as oral hypoglycemic drugs and regarded as a reliable indicator for
536 the efficacy of therapeutic agents [69-71]. Several α - amylase inhibitors including acarbose, miglitol
537 and voglibose are clinically useful to treat diabetes but these are expensive and have considerable
538 clinical side effects. Medicinal plants have great potential to retard the absorption of glucose by
539 inhibiting the saccharides hydrolyzing enzymes [72-74].

540 There was an attempt to explore the remarkable drugs from medicinal plants featured with
541 elevated potency and less adverse effects than existing drugs [75, 76]. Therefore, screening and
542 isolation of inhibitors from plants for these enzymes are escalating.

543 In the aforementioned context, our microencapsulated polyphenolic enriched powders were
544 investigated for α -amylase and α -glycosidase inhibition as shown in Figure 1G & 1H. Diverse classes
545 of polyphenolic compounds in the current PHF extract were detected likewise: flavonoids,
546 alkaloids, terpenoids, lignans, glycerophospholipid, prenol lipids and their derivatives (detailed in
547 Section 2.5), which eventually may considered for antidiabetic potential of microencapsulated
548 powders of current study. The treatment T_c (10% GA) demonstrated the highest inhibition at
549 concentration of 4 mg/mL, for alpha-amylase (93.33 ± 2.65 , with IC_{50} value $1.47 \text{ mg/mL} \pm 0.57$) and
550 alpha-glucosidase (73.39 ± 1.66 with IC_{50} value $2.03 \pm 0.45 \text{ mg/mL}$), representing highest antidiabetic
551 potential. Previously, none of investigation has yet been carried out on lyophilized aforementioned
552 microencapsulated PHF products. Additionally, there is no report on microencapsulation of
553 polyphenol enriched extract from PHF and their characterization for anti-diabetic potential purposes,
554 which eventually facilitate to take decision for commercialization of microencapsulated products *i.e.*
555 polyphenols enriched nutrient supplement.

556 *4.5. Bioavailable TP contents*

557 TP contents present in dialyzable fraction of final products were illustrated in Table 2 (mean
558 value \pm standard deviation). TP bioavailability ratios, articulated in the term of percentage, were
559 computed by using the equation as followed:

$$560 B_{av}(\%) = \frac{[TP]_{\text{Dialyzable}}}{[TP]_{\text{Total}}} \times 100$$

561 Where, B_{av} (%) represented the percentage (%) for TP bioavailability, whereas [TP] Total and
562 [TP] Dialyzable demonstrated TP concentrations after the PLE extraction method and in vitro
563 digestion procedure respectively.

564 Table 2.represented the Dialyzable TPs, were in the range of 8.21–13.32mg GAE/g. Figure 1F
565 depicted the bioavailability ratio (%) for all freeze-dried microencapsulated products. Treatment T_A

566 and T_C demonstrated the excellent bioavailability ratios (%) i.e. 57.25 and 54.64 % respectively, there
 567 was no significant difference in T_B and T_D. Furthermore No research has yet been conducted on in
 568 vitro dialyzability analysis of aforesaid microencapsulated PHF products.

569 Table 2: Average diameter and particle size distribution (Span) of the PHF extract microencapsulated
 570 with GA, GE, MD and their combinations by freeze-drying method.

Treatments	Average Diameter (μm)	Span
TA	151.13	1.74
TB	76.15	1.21
TC	92.79	2.88
TD	18.95	1.52


571 Treatment A (c; Treatment B (TB): Freeze-dried, with 5% GA and 5% MD; Treatment C (TC): Freeze-
 572 dried, with 10% GA; Treatment D (TD): Freeze-dried, with 10%.

573 4.6. Acute toxicity

574 No toxic effects and mortality were observed at a dose of 2000 mg/kg by gavage. Consequently,
 575 microencapsulated products of PHF extract were regarded as safe for consumption.

576 4.7. Bioactive Compounds from LC-ESI-QTOF-MS analysis

577 The ethanolic extract of freeze dried fine powder of PHF was a multifaceted mixture of
 578 compounds. Figure 3 characterized the chromatogram of said ethanolic extract. The bioactive
 579 compounds were recognized by means of the comparing retention times (RT) and MS/MS spectra
 580 granted by QTOF-MS with those of valid standards wherever obtainable and via elucidation of MS
 581 and MS/MS spectra from QTOF-MS merged with data available in literature. MS data of identified
 582 compounds has been recapitulated in the Table 3 including calculated *m/z* for molecular formulas
 583 provided, main fragment obtained by MS/MS, error and proposed compound for each peak. Diverse
 584 classes of polyphenolic compounds have been discovered in the ethanolic extract of PHF. The major
 585 detected classes of these polyphenolic bioactive compounds are flavonoids, alkaloids, terpenoids,
 586 lignans, glycerophospholipid and prenol lipids.



587

588 Figure 3: Chromatogram of the Ethanolic extract derived from freeze dried powder of PHF

Table 3: Bioactive Compounds identified in Ethanolic Extract of PHF

Peak No.	RT (min)	Assigned Compound Name	Elemental Composition	m/z [M+H] +	Difference (mDa)
1	8.773	Caffeic acid 4-sulfate	C9H8O7S	261.128	0.71
2	9.458	Steviol	C20H30O3	319.1329	-0.92
3	9.708	Antherospermidine	C18H11NO4	305.1541	0.15
4	9.904	ERIODICTYOL	C15H12O6	289.1231	-0.14
5	9.95	Phloretin	C15H14O5	275.1077	1.04
6	10.177	Zanthobisquinolone	C21H18N2O4	363.1589	0.57
7	10.384	Murrayazolinol	C23H25NO2	349.1795	0.72
8	10.639	Patuletin	C16H12O8	333.1488	0.34
9	10.746	Albanin d	C25H26O5	407.1849	0.84
10	10.834	3,5,8,3',4',5'-Hexahydroxyflavone	C15H10O8	319.1329	0.31
11	10.918	Myricetin	C15H10O8	319.1692	0.3
12	10.936	Dehydroneteonone	C19H12O6	393.2055	0.77
13	11.219	Carissanol	C20H24O7	377.1746	0.86
14	11.4	Epigallocatechin 3-O-cinnamate	C24H20O8	437.2313	-0.13
15	11.479	Catalpol	C15H22O10	363.195	0.8
16	11.528	Secoisolariciresinol	C20H26O6	363.1589	0.46
17	11.805	Quercetagetin 7-glucoside	C21H20O13	481.2572	-0.02
18	11.945	Cajaflavanone	C25H26O5	407.2208	-0.17
19	12.163	Barbatoflavan	C24H28O13	525.2828	0.9
20	12.348	Celastrol	C29H38O4	451.2469	0.04
21	12.484	6-Gingerol	C17H26O4	296.1487	-1.92
22	12.77	Euphorbia diterpenoid 3	C33H40O11	613.3348	0.89
23	13.017	2-Hexaprenyl-6-methoxyphenol	C37H56O2	534.3435	0.67
24	13.278	PE(P-16:0/18:2(9Z,12Z))	C39H74NO7P	701.3867	-1.1
25	13.569	Buddliedin A	C17H24O3	277.1385	-0.24

26	16.104	Phytosphingosine	C18H39NO3	318.2974	-0.04
27	17.059	1-EICOSENE	C20H40	282.2015	0.84
28	19.53	Tectorigenin	C16H12O6	301.1391	0.18
29	20.643	3-O-cis-Coumaroylmaslinic acid	C39H54O6	619.3973	-0.4
30	20.884	PA(18:3(6Z,9Z,12Z)/20:3(8Z,11Z,14Z))	C41H69O8P	721.4644	0.32
31	21.141	Eurysterol A sulfonic acid	C27H46O7S	515.3518	0.33
32	21.548	Citflavanone	C20H18O5	338.3391	1.25
33	21.698	Mesaconitine	C33H45NO11	631.4345	-0.17
34	22.01	Xanthoangelol	C25H28O4	393.294	0.44
35	22.385	PA(15:0/22:4(7Z,10Z,13Z,16Z))	C40H71O8P	711.4757	0.56
36	22.589	2',5,6-trimethoxyflavone	C18H16O5	312.3236	1.42
37	22.613	Ubiquinol-8	C49H76O4	729.5073	0.38
38	22.646	Epicalyxin J	C42H38O9	686.4852	0.14
39	22.967	Luteone	C20H18O6	354.37	1.64
40	23.177	Luteolin 4'-sulfate	C15H10O9S	366.3702	1.43
41	23.524	Quercetin 3-(6"-malonylglucoside)-7-glucoside	C30H32O20	713.5121	0.64
42	24.348	Phytoene	C40H64	545.1143	0.39
43	26.083	Epigallocatechin 3,3'-di-O-gallate	C29H22O15	610.1796	0.62
44	26.819	Kaempferol 3-(2",3"-diacetyl-4"-p-coumaroyl)rhhamnoside)	C34H30O14	663.4496	0.47
45	29.446	Delphinidin 3-(6"-malonyl-glucoside)	C24H23O15	684.1982	0.21

592 A total of 17th compounds were regarded as Flavanoids and their derivatives. These compounds
593 have been reported priory to possess anti-inflammatory, antinociceptive and antioxidant activities,
594 such as to inhibit lipid peroxidation, chelate redox-active metals and inhibit free-radical mediated
595 events and even increasing resistance to DNA strand breakage [77]. The brief description of each
596 bioactive compounds are elaborated; Eriodictyol, *m/z* 289.1231 [M+H]⁺ (4th detected compound) is a
597 flavonoid and further classified as flavanones. These are compounds containing a flavan-3-one
598 moiety, having a structure distinguished by a 2-phenyl-3, 4-dihydro-2H-1-benzopyran bearing a
599 ketone at the carbon C3 [78] have previously proven pro and antioxidant activities [79]. The
600 compound 8th (*i.e.* Patuletin *m/z* 333.1488 [M+H]), compound 10th (*i.e.* 3, 5, 8, 3', 4', 5'-
601 Hexahydroxyflavone, *m/z* 319.1329 [M+H] and compound 40th (*i.e.* Luteolin 4'-sulfate, *m/z* 366.3702
602 [M+H]) demonstrated the class flavonols. These are compounds that contain a flavone (2-phenyl-1-
603 benzopyran-4-one) backbone carrying a hydroxyl group at the 3-position. These compounds were
604 excessively present in coffee beans, herbs and spices, and pulses. Myricetin, *m/z* 319.1692 [M+H] (11th
605 detected compound) is a natural flavonoid present in plant kingdom including berries, grapes,
606 vegetables and variety of herbs, walnuts was also considered as rich dietary source of myricetin. This
607 bioactive flavonoid has previous proven anti-inflammatory and antioxidant activity [80]. The
608 compound (19th) Barbatoflavan belongs to flavonols *m/z* 525.2828 [M+H], demonstrated scavenging
609 properties towards the DPPH radicals [81]. The 32th peak is of Citflavanone, *m/z* 338.3391 [M+H],
610 belong to flavonoids class having anti-dengi, anti- malarial activities [82, 83].

611 Moreover, the Compound 9th (*i.e.* Albanin d, *m/z* 407.1849 [M+H]), compound 18th (*i.e.*
612 Cajaflavanone, *m/z* 407.2208 [M+H]) and compound 39th (*i.e.* luteone *m/z* 354.37 [M+H]), belongs to a
613 class typically known as 6-prenylated flavones. 6-prenylated flavones are flavones that features a C5-
614 isoprenoid substituent at the 6-position. These bioactive compounds are insoluble in aqueous
615 solution and designated as a faintly acidic compound. These compounds previously discovered in
616 fruits, peas and pulses and considered to be flavonoid lipid molecule. Other detected flavonoid lipid
617 molecule was the 2', 5, 6-trimethoxyflavone, *m/z* 312.3236 [M+H] (Peak 36) which are related to class
618 named as 6-o-methylated flavonoids. These bioactive flavonoids compounds had a structure contain
619 methoxy groups attached to the C6 atom of the flavonoid backbone. Tectorigenin (*i.e.* compound 28th,
620 *m/z* 301.1391 [M+H]) is an O-methylated isoflavone, Isoflavones are polycyclic compounds containing
621 a 2-isoflavene skeleton which bears a ketone group at the C4 carbon atom. The 12th detected
622 compound (*i.e.* dehydroneotenone, *m/z* 3393.2055 [M+H]) also recognized as Isoflavones.
623 Epigallocatechin 3-O-cinnamate, *m/z* 437.2313 [M+H] (Peak 14th) is a flavan-3-ol comprising a
624 benzopyran-3,5,7-triol attached with a 3,4,5-hydroxyphenyl moiety and Epigallocatechin 3,3'-di-O-
625 gallate, *m/z* 610.1796 [M+H], belongs to class catechin gallates, containing a gallate moiety
626 glycosidically linked to a catechin, thus, (-)-epigallocatechin 3,3'-di-gallate is also considered to be a
627 flavonoid lipid molecule.

628 In addition to aforementioned flavonoids, there was also detection of some other bioactive
629 compounds, which belong to sub class flavonoids glycosides: Quercetagetin 7-glucoside (Compound
630 17th, *m/z* 481.2572 [M+H]) and Quercetin 3-(6"-malonylglucoside)-7-glucoside (Compound 41th,*m/z*
631 713.5121 [M+H]) wererecognized as flavonoid-7-o-glycosides. These are phenolic compounds
632 containing a flavonoid moiety which is O-glycosidically linked to carbohydrate moiety at the C7-
633 position. These derivatives of flavonoids have priory proved strong antioxidant activity [84-85].

634 The 44th detected compound (Kaempferol 3-(2", 3"-diacetyl-4"-p-coumaroyl)rhhamnoside), *m/z*
635 663.4496 [M+H]) and 45th detected compound (Delphinidin 3-(6"-malonyl-glucoside), *m/z*
636 684.1982[M+H]) were generally categorized as flavonoid-3-o-glycosides. These bioactive compounds
637 contained a structure in which flavonoid moiety is O-glycosidically attached at the C3-position with
638 carbohydrate moiety. Catalpol *m/z* 363.195 [M+H] (Compound 15th) is a iridoid glucoside and has
639 been found to be present in large quantities in the root of *Romania glutinosa*. As a traditional medicine,
640 catalpol demonstrates a variety of biological activities including anticancer, neuro-protective, anti-
641 inflammatory, diuretic, hypoglycemic and anti-hepatitis virus effects. Previous studies have also
642 provided some clues that catalpol can affect energy metabolism through increasing mitochondrial

643 biogenesis, enhancing endogenous antioxidant enzymatic activities and inhibiting free radical
644 generation ultimately attenuates oxidative stress [86].

645 The peak 33th (*i.e.* Mesaconitine, m/z 631.4345 [$M+H$]) and peak 3rd (*i.e.* Antherospermidine, m/z
646 305.1541 [$M+H$ +]) were the member of group named alkaloids, later have a structure that contains
647 an aminoethylphenanthrene moiety. Atherosperminine has been cited to be in fruits and bark of
648 *Cryptocarya nigra* (Lauraceae) and have strong antioxidant, antimalarial and antimicrobial activities
649 [68]. Steviol, m/z 319.1329 [$M+H$] + designated as compound 2nd in our list of metabolites, is diterpene
650 alkaloids with a structure that is based on the kaurane skeleton. It possesses a [3, 2, 1]-bicyclic ring
651 system with C15-C16 bridge connected to C13, forming the five-membered ring D. This compound
652 was excessively found in different sorts of fruits and primarily responsible for the sweet taste of stevia
653 leaves. This compound is considered safe for human consumption and was approved as a food
654 additive by the Food and Drugs Administration (FDA) and European Food Safety Authority (EFSA)
655 it helps to reduce the oxidative stress [88]. In addition, the peak 6th is of Zanthobisquinolone, m/z
656 363.1589 [$M+H$] and peak 7th is of Murrayazolinol, m/z 349.1795 [$M+H$] belongs to the class Quinolines
657 and their derivatives, also alkaloid in nature. These are usually present in herbs, spices and some
658 fruits [89-91]. Various anti-malarial, antiparasitic, antibacterial and antiviral drugs do contain a major
659 constitute of aforementioned bioactive compound [92].

660 Besides flavonoid and alkaloids, these are also some compounds which have appreciable share,
661 belong to class prenol lipids. Likewise; the 20th detected compounds named as Celastrol, (plant-
662 derived triterpene) m/z 451.2469 [$M+H$], have previously proven antioxidant and anti-inflammatory
663 activity and prevented the neuronal degeneration in Alzheimer's disease (AD) [93]. The 23th
664 compound designated as 2-Hexaprenyl-6 methoxyphenol, m/z 534.3435 [$M+H$] is involving in the
665 ubiquinone biosynthesis pathway. It is formed from 3-Hexaprenyl-4-hydroxy-5-methoxybenzoate.
666 In the venture of ubiquinone biosynthesis monooxygenase Coq6T, the aforementioned compound
667 (23th) is eventually converted into 2-Hexaprenyl-6-methoxy-1, 4-benzoquinone. Ubiquinol 8, m/z
668 729.5073 [$M+H$] (compound 37th) belongs to organic compounds known as polyphenyl quinols. These
669 are compounds encompassing a poly-isoprene chain attached to a quinol (hydroquinone) at the
670 second ring position. It is the reduced configuration of ubiquinone-8. It plays a function as an electron
671 transporter in mitochondrial membrane, where it carries two electrons from either complex I (*i.e.*
672 NADH dehydrogenase) or complex II (*i.e.* succinate-ubiquinone reductase) to complex III. Phytoene,
673 m/z 545.1143 [$M+H$] (compound 42th) is member of class regarded as carotenes and further belongs to
674 family carotenoids. These are unsaturated hydrocarbons comprising of eight repeated isoprene units.
675 They have also previously proven antioxidant, anticancer activity and facilitate to reduce the
676 complications [94].

677 Amongst the known natural bioactive compounds in nature, terpenoids are considered to be of
678 approximately 60%. Plant terpenoids are used extensively for their aromatic qualities and play a role
679 in traditional herbal remedies, for instance; *Euphorbia* diterpenoids 3 (Compound 22th, m/z 613.3348
680 [$M+H$]) possesses a variety of different core frameworks and exhibit a diverse array of beneficial
681 activities, including anti-tumor, anti-inflammation, and immune-modulatory features, which was
682 regarded as excellent source in term of scientifically attraction [90, 91]. Buddleolin A (Compound
683 25th, m/z 277.1385 [$M+H$], a sesquiterpenoid based on a humulane skeleton (a novel terpenes from
684 *Buddleja globosa*) displaying selective antifungal activity against dermatophytes [95] in the same
685 manner, 3-O-cis-Coumaroylmaslinic acid (Compound 29th (Triterpenoids), m/z 619.3973 [$M+H$]), it is
686 normally present in fruits herbs and spices, and have ability to attenuate oxidative stress.

687 Lignans were usually found in fruits and have proved strong anticancer and antioxidant
688 activities. Among them, Secoisolariciresinol, m/z 363.1589 [$M+H$] (Compound 16th) belongs to class
689 dibenzylbutane lignans, containing a 2, 3-dibenzylbutane-1, 4-diol moiety. It was present in a number
690 of food items such as American butterfish, brazil nut, fireweed, and oriental wheat [96]. Carissanol,
691 m/z 319.1692 [$M+H$] (Compound 13th) on the other hand belongs to the class furanoid lignans
692 containing a 3, 4-dibenzylloxolan-2-ol moiety [97].

693 Phloretin (peak 5th, m/z 275.1077 [$M+H$]) and Xanthoangelol (peak 34th, m/z 393.294 [$M+H$])
694 belong to class chalcones and dihydrochalcones. Phloretin was previously reported to promote

695 potent anti-oxidative activities in peroxy nitrite scavenging and the inhibition of lipid peroxidation.
696 It is present in apples, pears and tomatoes, has been found to inhibit the growth of several cancer
697 cells [98], whereas Xanthoangelol (obligate intermediate in flavonoid biosynthesis) have antitumor
698 and anti-metastatic features [99].

699 Other detected compounds which were not discussed in detailed such as compound 24th, 30th,
700 35th, 26th are intermediate products of either metabolism or biosynthesis of amino acids, (phosphor
701 or/and sphingo) lipids. For instance, metabolite 24th represented a phosphatidylethanolamine, is an
702 anchor protein, produced as an intermediate in Glycosylphosphatidylinositol (GPI) anchor
703 biosynthesis pathway, while 30th compound *m/z* 721.4644 [M+H] and compound 35th, *m/z* 711.4757
704 [M+H] are the phosphatidic acids, produced in glycerolipid biosynthesis. The existences of such
705 compounds are mainly attributed to the seeds of *Hygrophila spinosa* T. Anders [100]. The 26th peak
706 recognized as Phytosphingosine, *m/z* 318.2974 [M+H], is an intermediate compound synthesized
707 between dihydro-shingosine and phytoceramide in shingophospholipid metabolism. Phospholipids
708 have diverse functions in varied processes of cell *i.e.* and apoptosis, cell propagation, cell to cell
709 interaction, differentiation. Furthermore, phytosphingosine is naturally occurring sphingoid bases,
710 fungi and plants are the rich source of phytosphingosine. It is structurally similar to sphingosine;
711 phytosphingosine possesses a hydroxyl group at C-4 of the sphingoid long-chain base.
712 phytosphingosine induces apoptotic cell death in human cancer cells by direct activation of caspase
713 8, and by mitochondrial translocation of Bax and subsequent release of cytochrome C into cytoplasm,
714 providing a potential mechanism for the anticancer activity of phytosphingosine [101].

715 Peak 21th showed the molecular formula C₁₇H₂₆O₄ and its MS spectrum presented a
716 fragmentation at *m/z* 296.1487 [M+H]⁺, which correspond to a compound of phenols class, it is the
717 active constituent of fresh ginger. Chemically, gingerol is a relative of capsaicin, belongs to the class
718 of organic compounds known as gingerols (phenols). These are compounds containing a gingerol
719 moiety, which is structurally characterized by a 4-hydroxy-3-methoxyphenyl group substituted at
720 the C6 carbon atom by a 5-hydroxy-alkane-3-one [102].

721 The metabolite 01, *m/z* 261.128 [M+H]⁺ have been referred to Caffeic acid 4-sulfate (polyphenol)
722 belongs to a class Cinnamic acids and their derivatives. Hydroxycinnamic acids are compounds
723 containing a cinnamic acid where the benzene ring is hydroxylated. It is one of the most
724 representative phenolic acids in fruits and vegetables which have excellent antioxidative potential and
725 anti-carcinogenic activity [90].

726 The peak 27th, Eicosene, belongs to a class regarded as unsaturated aliphatic hydrocarbons.
727 These are aliphatic hydrocarbons that have one or more double/triple bonds. 10-eicosene can be
728 found in herbs and spices; 10-Eicosene is usually present in herbs and spices and has good
729 antioxidant and antimicrobial activity [91, 92].

730 The 31th compound is of Eurysterol A sulfonic acid, *m/z* 515.3518 [M+H], A steroid sulfate that is
731 5 α -cholestane substituted by hydroxy groups at positions 5 and 6, a bridged oxolane at positions 8
732 and 19 and a sulfate group at position 3. It has proven cytotoxic and antifungal activities [91].
733 Epicalyxin J, *m/z* 686.4852 [M+H] (Compound 38th) is the diarylheptanoid are a relatively small class
734 of plant secondary metabolites. Diarylheptanoids consist of two aromatic rings (aryl groups) A
735 diarylheptanoid is an intermediate in the biosynthesis of phenylphenalenones in *Anigozanthos preissii*
736 it is strong potential against human fibro-sarcoma cells [103].

737 As can be concluded that the current PHF is the mixture of previously proven [31-34] health
738 promoting herbs' parts, so diversity and abundance of such detected antioxidant
739 substances/metabolites not only made sense but also verify the outcomes. Taking together, this is the
740 first study which exploited the metabolite profiling of said PHF enriched with antioxidants and their
741 evaluation for bioavailability and anti-diabetic potential after encapsulation.

742 5. Conclusions

743 In the current study, PHF polyphenolic extract was microencapsulated by utilizing GA, GE, and
744 MD as encapsulating wall materials, resulting powdered products had withholding capacity of TPC
745 more than 85% except T_D (68.22%), while TFC and TCT were found near to 60% except T_A.

746 Furthermore, elevated antioxidant activity was also revealed for T_B and T_C and reasonable for T_A and
747 T_D , representing noteworthy and positive correlation of antioxidant assays to all aforementioned
748 antioxidant components. Taking all results into consideration, T_B (5% GA and 5% MD) and T_C (10%
749 GA) showed the best performance attributable to the superior preservation of antioxidant
750 components and antioxidant activity by means of DPPH and β -carotene assays and significant for an
751 ABTS⁺ radical scavenging activity, augmented by low contents of moisture, water activity (aw),
752 particle dimension and elevated solubility, hygroscopicity and T_g . Additionally, the aforementioned
753 treatments also demonstrated the excellent morphological features with asymmetrical (irregular)
754 micro-particle structures, depicted lower prevalence of coarseness and crankiness. Moreover, T_B , T_C
755 and T_A also characterized the highest antidiabetic potential by reason of their significant inhibition
756 rate for alpha-amylase and alpha-glucosidase. In the context of bioavailability, T_B and T_C also
757 demonstrated the excellent bioavailability ratios (%) (i.e. more than 50% and 40% respectively). In
758 addition, no mice proved any toxicity sign at a dose of 2000 mg/kg by gavage for any treatment. In
759 the conclusive manner, we recommended the T_B and T_C as result of their incredible potential for its
760 usage in nutraceutical and functional products while masking the undesirable flavor distinctiveness
761 of herbs/herbal extracts.

762 Conflict of Interest: Authors declare no competing interests.

763 **Acknowledgment:** The author is pleased to state that this work is supported by National Natural Science
764 Foundation of China (Grant Nos. 31670064 and 31271812), and TaiShan Industrial Experts Program.

765 **Author Contributions:** Y.S. supervised this work. S.A.H. and A.H. performed all the experimental work. S.A.H.
766 wrote this manuscript. H.A.R.S. edited and reviewed the whole manuscript and provided suggestions to main
767 authors about overall research plan. All authors read and approved the final manuscript. Y.N, T.N and Y.W
768 assisted in anti-diabetic assay and data analysis. References

769 References

- 770 1. Kumar, P.S and Sudha, S. Evaluation of alpha amylase and alpha glucosidase inhibitory properties of
771 selected seaweeds from Gulf of Mannar. *Inter. research J. pharm.* **2012**, *3*, 128-130.
- 772 2. Lavelli, V. et al. Grape skin phenolics as inhibitors of mammalian α -glucosidase and α -amylase effect of
773 food matrix and processing on efficacy. *Food Func.* **2016**, *7*, 1655-1663.
- 774 3. Kazeem, M.I., Adamson, J.O. and Ogunwande, I.A. Modes of Inhibition of α -Amylase and α -Glucosidase
775 by Aqueous Extract of *Morinda lucida* Benth Leaf. *BioMed. Research Inter.* **2013**. ID: 527570, 1-6.
- 776 4. Heise, T. et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin
777 glargin in people with type 1 diabetes. *Diabetes* **2004**, *53*, 1614-1620.
- 778 5. Hong, S. Y. et al. Hepatitis B and C virus infection and diabetes mellitus: A cohort study. *Sci. Rep.* **2017**,
779 *7*, 4606.
- 780 6. Krischer, J. P. et al. Genetic and environmental interactions modify the risk of diabetes-related
781 autoimmunity by 6 years of age: the teddy study. *Diabetes care* **2017**, *40*, 1194-1202(2017).
- 782 7. Bao, W. et al. Prepregnancy low-carbohydrate diet scores and the risk of gestational diabetes mellitus:
783 a prospective cohort study. *Am. J. Clin. Nutr.* **2013**, *99*, 1378-1384.
- 784 8. Jonczyk-Skorka, K. and Kowalski, J. The assessment of risk factors for glucose metabolism
785 disorders. *Pol. Merkur. Lekarski.* **2017**, *42*, 241-246.
- 786 9. Fridlyand, L. E. and Philipson, L. H. Oxidative reactive species in cell injury: Mechanisms in diabetes
787 mellitus and therapeutic approaches. *JAMA*. **2005**, *1066*, 136-151.
- 788 10. Ohkuwa, T., Sato, Y. and Naoi, M. Hydroxyl radical formation in diabetic rats induced by
789 streptozotocin. *Life Sci.* **1995**, *56*, 1789-1798.
- 790 11. Dahech, K. S. et al. Oral administration of levan polysaccharide reduces the alloxan-induced oxidative
791 stress in rats," *Inter'l J. Biological Macro.* **2011**, *49*, 942-947.
- 792 12. Suleria, H.A et al. Onion: Nature protection against physiological threats. *Crit. Rev. Food Sci. Nutr.* **2015**, *55*,
793 50-66.
- 794 13. Hurrel, S and Hsu, W.H. The etiology of oxidative stress in insulin resistance *Biomed. J.* **2017**, *40*, 257 -262.
- 795 14. Li, A.N. et al. Resources and biological activities of natural polyphenols. *Nutrients* **2014**, *26*, 6020-6047.
- 796 15. Mojzer, E. B. et al. Polyphenols: Extraction methods, antioxidative action, bioavailability and
797 anticarcinogenic effects. *Molecules* **2016**, *21*, 1-38.

798 16. Hameed, A. et al. Antioxidants Potential of the Filamentous Fungi (*Mucor circinelloides*). *Nutrients* 2017, 9,
799 1101–1121.

800 17. Ameer, K. et al. Green extraction methods for polyphenols from plant matrices and their byproducts: a
801 review. *Compr. Rev. Food Sci. Food Safe.* 2017, 16, 295–315.

802 18. Spinella, M. The importance of pharmacological synergy in psychoactive herbal medicines. *Altern. Med.
803 Rev.* 2002, 7, 130–137.

804 19. Chorgade, M.S. *Drug Discovery and Development*. Hoboken, New Jersey: USA, 2007, Vol.

805 20. Pole, S. *Ayurvedic Medicine: The Principles of Traditional Practice*. Jessica Kingsley Publishers, London,
806 2013.

807 21. Fang, Z., and Bhandari, B. Effect of spray drying and storage on the stability of bayberry polyphenols. *Food
808 Chem.* 2011, 129, 1139–1147.

809 22. Garber A. J and Karlsson, F.O. Treatment of dyslipidemia in diabetes. *Endocrinol. Metabol. Clinics North
810 America* 2001, 30, 999–1010.

811 23. Lee, B.R. et al. Amelioration of streptozotocin- induced diabetes by *Agrocybe chaxingu* polysaccharide,”
812 *Molecul. Cells* 2010, 29, 349–354.

813 24. Hu, S. H. et al. Antihyperglycemic effect of polysaccharide from fermented broth of *Pleurotus citrinopileatus*.
814 *App. Micro.Biotech.* 2006, 70, 107–113.

815 25. Silva, P. I. et al. Parameter optimization for spray-drying microencapsulation of jaboticaba (*Myrciaria
816 jaboticaba*) peel extracts using simultaneous analysis of responses. *J. Food Engin.* 2013, 117, 538–544.

817 26. Tonon, R. V. et al. Physicochemical and morphological characterization of açaí (*Euterpe oleracea* Mart.)
818 powder produced with different carrier agents. *Inter. J. of Food Sci. Tech.* 2009, 44, 1950–1958.

819 27. Cano-Chauca, M., Stringheta, P. C., Ramos, A. M., and Cal-Vidal, J. Effect of the carriers on the
820 microstructure of mango powder obtained by spray drying and its functional characterization. *Inno. Food
821 Sci. Emer. Tech.* 2005, 6, 420–428.

822 28. Tonon, R.V., Brabet, C., and Hubinger, M. D. Influence of process conditions on the physicochemical
823 properties of açaí (*Euterpe oleracea* Mart.) powder produced by spray drying. *J. Food Engin.* 2008, 88, 411–
824 418.

825 29. Fang, Z and Bhandari, B. Effect of spray drying and storage on the stability of bayberry polyphenols. *Food
826 Chem.* 2011, 129, 1139–114.

827 30. Mahdavi et al. Microencapsulation optimization of natural anthocyanins with maltodextrin, gum Arabic
828 and gelatin. *Int'l. J. Biol. Mac.* 2016, 85, 379–385.

829 31. Varghese, C.P. et al. Antioxidant and anti-inflammatory activity of *Eurycoma longifolia* Jack, A traditional
830 medicinal plant in Malaysia. *Inter'l J. Pharm. Sci. Nanotech.* 2013, 5, 1875–1878.

831 32. Shahzad, M. et al. The Antioxidant Effects of *Radix Astragali* (*Astragalus membranaceus* and related Species)
832 in Protecting Tissues from Injury and Disease. *Curr. Drug Target.* 2016, 17, 1331–1340.

833 33. Patra, A. et al. Phytochemical and pharmacological potential of *Hygrophila spinosa* T. Anders. *Pharma. Rev.*
834 2009, 3, 330–341.

835 34. Sharma, G and Kumar, M. Antioxidant and modulatory role of *Chlorophytum borivilianum* against arsenic
836 induced testicular impairment. *J. Environ. Sci.* 2012, 24, 2159–65.

837 35. Miller, N.J. et al. A novel method for measuring antioxidant capacity and its application to monitoring the
838 antioxidant status in premature neonates. *Clin. Sci.* 1993, 84, 407–412.

839 36. Brand-Williams, W., Cuvelier, M. E., and Berset, C. Use of free radical method to evaluate antioxidant
840 activity. *LWT – Food Sci. Tech.* 1995, 28, 25–30 (1995).

841 37. AOAC. Official methods of analysis of the association of official analytical chemists. 1990, Washington, DC.

842 38. Cano-Chauca, M. et al. Effect of the carriers on the microstructure of mango powder obtained by spray
843 drying and its functional characterization. *Inno. Food Sci. Emer. Tech.* 2005, 6, 420–428.

844 39. Caparino, O. A. et al. Effect of drying methods on the physical properties and microstructures of mango
845 (Philippine ‘Carabao’ var.) powder. *J. Food Engin.* 2012, 111, 135–148.

846 40. Young-In, K. et al. Inhibitory potential of wine and tea against α -amylase and α -glucosidase for
847 management of hyperglycemia linked to type 2 diabetes. *J. Food Biochem.* 2008, 32, 15–31.

848 41. Apostolidis, E., Kwon, Y.I. and Shetty, K. Inhibitory potential of herb, fruit, and fungi-enriched cheese
849 against key enzymes linked to type 2 diabetes and hypertension. *Inn. Food Sci. Emerg. Technol.* 2007, 8, 46–
850 54.

851 42. Moreda-Pineiro, J. et al. Bioavailability assessment of essential and toxic metals in edible nuts and seeds. *Food Chem.* **2016**, *205*, 146–154.

852 43. OECD. OECD Guidelines for the testing of chemicals, repeated dose 28-day oral toxicity study in rodents. *1995*, 407.

853 44. Golde, P. H., van der Westelaken, M., Bouma, B. N., and van de Wiel, A. Characteristics of piraltin, a polyphenol concentrate, produced by freeze-drying of red wine. *Life Sci.* **2004**, *74*, 1159–1166.

854 45. Kuck, L.S., and Norena, C. P. Z. Microencapsulation of grape (*Vitis labrusca* var. Bordo) skin phenolic extract using gum arabic, polydextrose, and partially hydrolyzed guar gum as encapsulating agents. *Food Chem.* **2016**, *194*, 569–576.

855 46. Mathiowitz, E., Kreitz, M. R. and Brannon-Peppas, L. Microencapsulation. In E. Mathiowitz (Ed.), *Encyclopedia of controlled drug delivery*. John Wiley and Sons, New York, USA, 1999, 493–553.

856 47. Ramírez, M. J., Giraldo, G. I. and Orrego, C. E. Modeling and stability of polyphenol in spray-dried and freeze-dried fruit encapsulates. *Powder Tech.* **2015**, *277*, 89–96.

857 48. Burin, V. M. et al. Anthocyanins: Optimization of extraction from Cabernet Sauvignon grapes, microencapsulation and stability in soft drink. *Inte. J. Food Sci. Tech.* **2011**, *46*, 186–193.

858 49. Souza, V. B. et al. Effect of spray drying on the physicochemical properties and color stability of the powdered pigment obtained from vinification byproducts of the Bordo grape (*Vitis labrusca*). *Food and Biopro. Process.* **2015**, *93*, 39–50.

859 50. Franceschinis, L. et al. Physical and functional properties of blackberry freeze- and spray-dried powders. *Dry. Tech.* **2014**, *32*, 197–207.

860 51. Ezhilarasi, P. N. et al. Freeze drying technique for microencapsulation of Garcinia fruit extract and its effect on Bread quality. *J. Food Eng.* **2013**, *117*, 513–520.

861 52. Gurak, P. D., Cabral, L. M. C., & Rocha-Leao, M. H. Production of grape juice powder obtained by freeze-drying after concentration by reverse osmosis. *Brazilian Archives Bio. Tech.* **2013**, *56*, 1011–1017.

862 53. Cortes-Rojas, D. F., Souza, C. R. F. and Oliveira, W. P. Optimization of spray drying conditions for production of *Bidens pilosa* L. dried extract. *Chem. Engin. Res. Design* **2015**, *93*, 366–376 (2015).

863 54. Kuck, L. S. and Norena, C. P. Z. Microencapsulation of grape (*Vitis labrusca* var. Bordo) skin phenolic extract using gum arabic, polydextrose, and partially hydrolyzed guar gum as encapsulating agents. *Food Chem.* **2016**, *194*, 569–576.

864 55. Çam, M., İçyer, N. C. & Erdogan, F. Pomegranate peel phenolics: Microencapsulation, storage stability and potential ingredient for functional food development. *LWT – Food Sci. Tech.* **2014**, *55*, 117–123.

865 56. Moreira, G.E.G. et al. Physical properties of spray dried acerola pomace extract as affected by temperature and drying aids. *LWT – Food Sci. Tech.* **2009**, *42*, 641–645.

866 57. Khazaei, K.M., Jafari, S.M., Ghorbani, M. and Kakhki, A. H. Application of maltodextrin and gum Arabic in microencapsulation of saffron petal's anthocyanins and evaluating their storage stability and color. *Carbo. Polym.* **2014**, *105*, 57–62.

867 58. Man, Y. B. C., Irwandi, J. and Abdullah, W. J. W. Effect of different types of maltodextrin and drying methods on physico-chemical and sensory properties of encapsulated durian flavor. *J. Sci. Food and Agri.* **1999**, *79*, 1075–1080.

868 59. Sawale, P.D. et al. Release Characteristics of Polyphenols from Microencapsulated Terminalia Arjuna Extract: Effects of Simulated Gastric Fluid. *Int. J. Food Proper.* **2017**, *20*, 3170-3178.

869 60. Adhikari, B., Howes, T., Bhandari, B.R. and Troung, V. Effect of addition of maltodextrin on drying kinetics and stickiness of sugar and acid-rich during convective drying: Experiments and modelling. *J. Food Engineer.* **2004**, *62*, 53–68.

870 61. Mitchell, H. L. The role of the bulking agent polydextrose in fat replacement. In S. Roller & S. A. Jones (Eds.), *Handbook of fat replacers*. Boca Raton: CRC Press, **1996**, 235–249.

871 62. Kapoor, M.P., and Juneja, L.R. Partially hydrolyzed guar gum dietary fiber. *Fiber ingredients: Food applications and health benefits*. In S. S. Cho & P. Samuel (Eds.), Boca Raton: CRC Press, **2009**, 70–120.

872 63. Al-Assaf, S., Philips, G. O. and Williams, P. A. Studies on Acacia exudates gums: Part II. Molecular weight comparison of the Vulgares and Gummiferae series of Acacia gums. *Food Hydro.* **2005**, *19*, 661–667.

873 64. Nunes, G. L. et al. Microencapsulation of freeze concentrated *Ilex paraguariensis* extract by spray drying. *J. Food Engin.* **2015**, *151*, 60–68.

903 65. Kuck, L. S. and Norena, C. P. Z. Microencapsulation of grape (*Vitis labrusca* var. Bordo) skin phenolic extract
904 using gum arabic, polydextrose, and partially hydrolyzed guar gum as encapsulating agents. *Food Chem.*
905 2016, 194, 569–576.

906 66. Kuang, S.S. et al. Microencapsulation as a tool for incorporating bioactive ingredients into food. *Crit. Rev.*
907 *Food Sci. Nutr.* 2010, 50, 951–68.

908 67. Chen, C., Chi, Y. J. and Xu, W. Comparisons on the functional properties and antioxidant activity of spray-
909 dried and freeze-dried egg white protein hydrolysate. *Food Biopro. Tech.* 2012, 5, 2342–2352.

910 68. Saikia, S., Mahnot, N. K. and Mahanta, C. L. Optimization of phenolic extraction from *Averrhoa carambola*
911 pomace by response surface methodology and its microencapsulation by spray and freeze drying. *Food*
912 *Chem.* 2015, 171, 144–152.

913 69. Kazeem, M. I., Ogunbiyi, J. V. and Ashafa, A.O.T. In vitro Studies on the Inhibition of α -Amylase and α -
914 Glucosidase by Leaf Extracts of *Picrali manitida* (Stapf) Gin H, Rigalleau V. Post-prandial hyperglycemia
915 and Diabetes. *Diab. Metabol.* 2000, 26, 265–272.

916 70. Sima, A.A, Chakrabarti, S. Long-term suppression of postprandial hyperglycaemia with acarbose retards
917 the development of neuropathies in the BB/W-rat. *Diabetologia* 1992, 35, 325–30.

918 71. Kwon, Y.I., Apostolidis, E. and Shetty, K. Evaluation of pepper (*Capsicum annuum*) for management of
919 diabetes and hypertension. *J. Food Biochem.* 2007, 31, 370–385.

920 72. Sultan, M. T. et al. Immunity: plants as effective mediators. *Cri. Rev. Food Sci. Nutr.* 2014, 54, 1298–1308.

921 73. Kim, J.S., Kwon, C.S., Son, K.H. Inhibition of α -glucosidase and amylase by Luteolin, a flavonoid. *Biosci.*
922 *Biotech. Biochem.* 2000, 64, 2458–2461.

923 74. Matsui, T., Ogunwande, I.A., Abesundara, K.J.M. and Sumoto, K.M. Anti-hyperglycemicpotential of
924 natural products. *Mini-Reviews in Med. Chem.* 2006, 6, 349–356.

925 75. Matsuda, H., Morikawa, T. and Yoshikawa, M. Antidiabetogenic constituents from several natural
926 medicines. *Pure and Appl. Chem.* 2002, 74, 1301–1308.

927 76. Ogunwande, I.A., Matsui, T., Fujise, T. and Matsumoto, K. α -Glucosidase inhibitory profile of Nigerian
928 medicinal plants in immobilized assay system. *Food Sci. Tech. Res.* 2007, 13, 169–172.

929 77. Eldeen, A. et al. Evaluation of antioxidant, anti-inflammatory, and antinociceptive properties of aerial parts
930 of *Vicia sativa* and its flavonoids. *J. Nat. Remed.* 2004, 4, 81–96.

931 78. Tisserant, L.P. et al. 13C NMR and LC-MS Profiling of Stilbenes from Elicited Grapevine Hairy Root
932 Cultures. *J. Nat. Prod.* 2016, 79, 2846–2855.

933 79. Chobot, V. et al. Pro- and Antioxidant Activity of Three Selected Flavan Type Flavonoids: Catechin,
934 Eriodictyol and Taxifolin. *Int. J. Mol. Sci.* 2016, 17, 1986–1995.

935 80. Hassan, S.M. et al. Protective effects of apigenin and myricetin against cisplatin-induced nephrotoxicity in
936 mice. *Pharm. Biol.* 2017, 551, 766–774.

937 81. Cuendet, M. et.al. Flavonoids and phenylpropanoid derivatives from *Campanula barbata*. *Phytochem.* 2001,
938 56, 631–636.

939 82. Tang, L. et al. Screening of anti-dengue activity in methanolic extracts of medicinal plants. *BMC Comp.*
940 *Altern. Med.* 2008, 12, 1186–1196.

941 83. Khaomek, P. et al. In vitro antimalarial activity of prenylated flavonoids from *Erythrina fusca*. *J. Nat.*
942 *Med.* 2008, 62, 217–220.

943 84. Zheng, Y. et al. Antioxidant Activity of Quercetin and Its Glucosides from Propolis: A Theoretical Study.
944 *Sci. Rep.* 2017, 7, 7543–7554.

945 85. Agostino, M. et al. Quercetagetrin 6-O- β -d-glucopyranoside from *Tagetes mandonii*. *Phytochem.* 1997, 45, 20–
946 202.

947 86. Zhang, Y. et al. Catalpol attenuates oxidative stress and promotes autophagy in TNF-a-exposed HAECS by
948 up-regulating AMPK. *RSC Adv.* 2017, 7, 52561.

949 87. Nasrullah, A. et al. Antiplasmodial Alkaloids from the Bark of *Cryptocarya nigra* (Lauraceae). *Molecules*
950 2013, 18, 8009–8017.

951 88. Aceves, L. et al. Reduction of the Oxidative Stress Status Using Steviol Glycosides in a Fish Model (*Cyprinus*
952 *carpio*). *BioMed Research Inter.* 2017, 9, 235–294.

953 89. Shmuel, Y. Dictionary of food compounds with CD-ROM: Additives, flavors, and ingredients. Boca Raton:
954 Chapman & Hall/CRC, 2004.

955 90. Buckingham, J., Baggaley, K.H., Roberts, A.D. & Szabo, L.F. Dictionary of Alkaloids, Second Edition with
956 CD-ROM, 2010. <https://books.google.com/books?id=mynNBQAAQBAJ>

957 91. Buckingham, J., & Munasingh, V.R.N. Dictionary of Flavonoids, First edition with CD-ROM, 2007.

958 92. Palluotto, F. et al. Quinolino [3, 4-b] quinoxalines and pyridazino [4,3-c] quinoline derivatives: Synthesis, inhibition of topoisomerase II α , G-quadruplex binding and cytotoxic properties. *Eur. J. Med. Chem.* 2016, 123, 704-717.

959 93. Allison, A.C. et al. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for

960 Alzheimer's disease. *Prog. Neu. Bio. Psych.* 2001, 25, 1341-57.

961 94. Fiedor, J. and Brrda. Potential Role of Carotenoids as Antioxidants in Human Health and Disease. *Nutrients*

962 2014, 6, 466-488.

963 95. Mensah, A.Y. et al. Known and novel terpenes from *Buddleja globosa* displaying selective antifungal activity

964 against dermatophytes. *J. Nat. Prod.* 2000, 63, 1210-1213.

965 96. Chun, Hu. et al. Antioxidant activities of the flaxseed lignan secoisolariciresinol diglucoside, its aglycone

966 secoisolariciresinol and the mammalian lignans enterodiol and enterolactone *in vitro*. *Food Chem. Toxi.* 2007,

967 45, 2219-2227.

968 97. Wangteeraprasert, R. et al. Bioactive compounds from *Carissa spinarum*. *Phyto. Res.* 2012, 26, 1496-1499.

969 98. Stangl, V. et al. The flavonoid phloretin suppresses stimulated expression of endothelial adhesion

970 molecules and reduces activation of human platelets. *J. Nutr.* 2005, 135, 172-178.

971 99. Sumiyoshi, M. et al. Antitumor and antimetastatic actions of xanthoangelol and 4-hydroxyderricin isolated

972 from *Angelica keiskei* roots through the inhibited activation and differentiation of M2 macrophages.

973 *Phytomed.* 2015, 15, 22, 759-767.

974 100. Cui, L. and Decker, E.A. Phospholipids in foods: pro-oxidants or antioxidants. *J. Sci. Food Agri.* 2016, 96,

975 18-31.

976 101. Dugasani S, Pichika MR. et al. Comparative antioxidant and anti-inflammatory effects of [6]-gingerol, [8]-

977 gingerol, [10]- gingerol and [6]-shogaol. *J. Ethnopharmacol.* 2010, 127, 515-520.

978 102. Park, M.T. et al. Phytosphingosine induces apoptotic cell death via caspase 8 activation and Bax

979 translocation in human cancer cells. *Clin. Cancer Res.* 2003, 9, 878-885.

980 103. Tezuka, Y. et al. Eleven Novel Diarylheptanoids and Two unusual Diarylheptanoid Derivatives from the

981 Seeds of *Alpinia blepharocalyx*. *J. Nat. Prod.* 2001, 64, 208-213.

982

983